704. Cellular Immunotherapies: Cellular Therapies for Lymphomas

91 ASH denotes this abstract as clinically relevant

Manali Kamdar, MD1, Scott R. Solomon, MD2, Jon E. Arnason, et al.

Liso-cel led to a statistically significant and clinically meaningful improvement in EFS compared to SOC as second-line therapy in patients with primary refractory LBCL versus Or relapse ≤ 12 months after first-line therapy. [Nbsp] This also applies to the   major secondary efficacy endpoints (CR rate and PFS). The safety results in second-line treatment were consistent with the Liso-cel safety profile in third-line therapies   or later LBCL. There were no new security concerns.



Emmanuel Bachy, Steven Le Gouill, Roberta Di Blasi, et al.

In this study, there was no OS difference between Axi-Cel and Tisa-Cel. Axi-cel achieved higher ORR and CRR and significantly longer PFS compared to tisa-cel. However, higher efficacy was associated with higher neurotoxicity with Axi-cel. Young and/or fit patients can benefit most from Axi-cel. Tisa-cel is most beneficial for elderly and/or not fit patients.



Sattva S. Neelapu, Julio C. Chavez, Alison R. Sehgal, et al.

The long-term follow-up in ZUMA-5 showed a significant and sustained benefit for axi-cel in patients with iNHL. In Follicular Lymphoma there were consistently high response rates with a median DOR of 38.6 months. This affected 57 percent of eligible patients. With mantle cell lymphoma, the results seemed to improve with a longer follow-up period: the median DOR and OS had not yet been reached. Axi-cel continued to show a manageable safety profile and no new safety signals emerged.


94 ASH denotes this abstract as clinically relevant

JIA Wei, Min Xiao, Zekai Mao, et al.

The CAR-T-cell cocktail therapy is effective in TP53-disturbed r / r aggressive B-NHL. The inclusion of CAR-T cell infusions in the ASCT can further improve the long-term outcome of these patients.



Nirav N. Shah, Joanna C. Zurko, Dina Schneider, et al.

Bispecific LV20.19 CAR-T cells expanded with IL7 + 15 resulted in an effective high ORR and there were low rates of grade ≥3 CRS or ICANS for R / R-B-cell NHL. The treatment is safe. The MCL outcomes had an ORR of 100 percent without relapses.



Jae H Park, Craig S. Sauter,  M. Lia Palomba, et al.

Giving anakinra early seems safe and feasible. The IL-1 receptor reduced the rates of both severe CRS and ICANS with comparable response rates in adult patients with R/R-B-cell lymphoma who received CD19-CAR-T cells. Severe CRS and ICANS rates were 6 percent each with relatively little use of tocilizumab (29%) and corticosteroids (19%). The rate of severe ICANS for axicabtagene was 4 percent.